Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) an emerging specialty pharmaceutical company, announced that additional safety data are being highlighted from its Phase 3 trial of EXPARELâ„¢ (bupivacaine extended-release liposome injection) in bunionectomy. The data showed comparable safety in wound healing and significantly improved efficacy in pain reduction compared to placebo.